Since its inception, ENDORENEW has been at the forefront of medical research and therapeutic development for both Asherman syndrome (AS) and thin endometrium (TE). The company’s commitment to advancing scientific understanding and treatment options for these conditions is reflected in its significant milestones, starting from early clinical trials to cutting-edge research publications. Below is a timeline that outlines the key achievements and ongoing efforts that have defined PAULA’s journey.
Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study.
Status assigned to CD133+ for the treatment of AS, considered a rare disease.
20 patients were recruited to assess the effects of the stem cell treatment under a controlled environment. The Phase I/II study was completed in 2024, with results published in 2026 in a high impact journal.
Use of Autologous Human CD133+ Bone Marrow–Derived Stem Cells (BMDSCs) for the Treatment of Asherman Syndrome.
Decoding the endometrial niche of Asherman’s Syndrome at single-cell resolution.
Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial.
Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial. Nature Communications. 2026;17:1093.
Available at: https://doi.org/10.1038/
Phase 1/2 clinical trial demonstrating the safety and potential effectiveness of CD133+ stem cell therapy in women with moderate to severe Asherman Syndrome.
Decoding the endometrial niche of Asherman’s syndrome at single-cell resolution. Nature Communications. 2023;14:5890.
Available at: https://doi.org/10.1038/
Advanced single-cell research analysing how Asherman’s syndrome affects the cellular environment of the endometrium.
Patent US11129851B2. 2021.
Available at: https://patents.google.com/
Official patent describing the protected medical technology behind this therapeutic approach.
Community Register of medicinal products for human use. 2017.
Available at: https://ec.europa.eu/health/
Official European regulatory registry confirming the orphan drug designation and regulatory status of the therapy.
Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study. Human Reproduction. 2016;31(5):1087–
Available at: https://doi.org/10.1093/
First clinical pilot study evaluating the safety and reproductive outcomes of CD133+ stem cell therapy in patients with severe endometrial damage.
Endorenew has received funding from:
The Torres Quevedo Program 2022 of the Ministry of Science and Innovation (reference number PTQ2022-012376) for the project titled «Application of New Embryo Transfer Methodologies for the Improvement of Reproductive Prognosis in Severe Cases of Asherman’s Syndrome,» with a grant of €114,674 for the period 2024-2027.
